Specialty Pharmacy

Acquisition includes 33 retail drugstore locations and a specialty pharmacy serving patients with complex or chronic diseases.

ApproveRx is an online platform that streamlines the prior authorization process for pharmacies and prescribers.

Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the methods BioPlus uses to improve patient medication adherence.

Sunscreen application to infant opossums leads to 10-fold reduction in pre-melanotic lesions.

More than 2 years after ceasing antiretroviral therapy, HIV is again detectable in "Mississippi baby."

Targeted therapies used in conjunction with chemotherapy may offer benefits to patients with triple-negative breast cancer.

A study indicates that BPA-induced cancers in female rats may lead to tumors with evidence of both genetic and epigenetic changes.

Michael Nameth, RPh, MBA, chief executive officer of Aureus Health Services, discusses the growth of his company as a mid-size specialty pharmacy.

Researchers at the Dana-Farber Cancer Institute and Brigham and Women's Hospital have tested a nanomedicine technology in mice formulated to precisely target myeloma cancer cells with a novel bortezomib delivery system.

Study indicates hyperlipidaemia increases risk of breast cancer by 1.64 times.

Executive at Pfizer discusses the various regulatory roadblocks and market challenges for biosimilars in a Q&A with Specialty Pharmacy Times.

Bill Barre, RPh, vice president of business development at MedImpact Healthcare Systems, discusses how MedImpact meets the needs of specialty pharmacies.

People with high levels of sedentary behavior are more susceptible to 3 types of cancer.

Diabetes control worsened for patients with diabetes who received or were receiving androgen deprivation therapy for prostate cancer.

Study finds cancer management guidelines need to be updated to account for patients with HIV.

Suzanne Tschida, PharmD, BCPS, vice president of specialty benefit and outcomes strategy at OptumRx, talks about recent research regarding specialty pharmacy and patient outcomes.

Questionnaires given to patients with psoriasis predicted probable psoriatic arthritis in a significant number of patients.

Radiation oncologists and urologists surveyed indicate the primary treatment provided by the other specialty is being overused.

In addition to finding no association between aspirin use and reduced risk of breast cancer, researchers find non-breast cancer deaths higher among aspirin users.

Biologic agent golimumab effective over 5-year span in treating disease symptoms and improving quality of life.

Researchers continue pursuit of vaccine that will lead to HIV cure.

Patients treated for Hodgkin's disease during childhood or adolescence have a greater risk of developing secondary breast cancer later in life, particularly if they receive radiotherapy during puberty.

Researchers in the United Kingdom have identified a blood test for circulating free DNA that may help physicians predict whether or not a patient with breast cancer is likely to respond to an initial round of chemotherapy, enabling earlier initiation of alternate treatments.

Howard Barsky, chief information officer for Armada Health Care, discusses the benefits of enhanced data analytics programs and how they can benefit specialty pharmacies.

Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses how BioPlus has changed to better meet the needs of their patients.

Program allows health care professionals to better access medication history.

Thomas Cohn, chief strategy officer at Armada Health Care, discusses the long term impact of the Affordable Care Act on specialty pharmacies.

Researchers find interventions targeting mental health problems and substance abuse can improve treatment outcomes.

Caregivers give thoughts on attributes they are looking for in DMD treatment.

Gary Rice, RPh, MS, MBA, vice president of clinical services at Diplomat Specialty Pharmacy discusses effective counseling of rheumatoid arthritis patients on biologic DMARD therapy.